What question did this study set out to answer?

The research aims to characterize cytokine release syndrome (CRS) associated with talquetamab in patients with relapsed/refractory multiple myeloma.

March 19, 2026Open Access

Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma

Key Points

The research aims to characterize cytokine release syndrome (CRS) associated with talquetamab in patients with relapsed/refractory multiple myeloma.
Analysis of adverse events related to talquetamab therapy.
Description of clinical implications for managing CRS.
Review of patient responses and treatment outcomes.
CRS is a common adverse event during talquetamab treatment.
Effective management strategies for CRS were identified.
Implications for improving patient outcomes during therapy were highlighted.

Abstract

Introduction Cytokine release syndrome (CRS) is a common adverse event associated with T-cell redirection therapies (TCRT), including talquetamab, the first GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). We describe CRS with talquetamab and implications for clinical practice.

Mark Helpful

Bookmark

Relay

View Full Paper